Additional rationale for keeping the glycan as part of the vaccine is that, although the Fba peptide is unique to C. albicans, responses against the β-(Man)3 would be expected to protect against infection with a variety of other clinically important Candida species [15], including C. tropicalis[29], [44], C. lusitaniae[45], C. guilliermondii[46], [47] and the majority of C. glabrata strains [48], [49]. This evidence concerns the gene FBXO3 and infection.